Novartis Fabhalta Wins Traditional FDA Approval in IgAN, Raising the Bar for Vera and Otsuka

On July 17, 2026, the FDA granted Novartis traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. The approval, based on Phase 3 APPLAUSE-IgAN data, converts Fabhalta’s initial accelerated approval from August 2024 into a full approval. Novartis closed at $155.01 on July 24.

The distinction between traditional and accelerated approval matters more than most coverage suggests. Accelerated approval is conditional: the FDA grants it based on a surrogate endpoint (like proteinuria reduction) and requires a confirmatory trial to verify clinical benefit. If the confirmatory trial fails, the drug can be withdrawn. Traditional approval means the FDA has seen enough evidence of actual clinical benefit to grant full approval with no confirmatory requirement hanging over the label.

Why traditional approval is a competitive weapon

Fabhalta is not the first IgAN drug to reach traditional approval. Calliditas’ Tarpeyo (budesonide) got there in December 2023, going from accelerated approval in 2021 to full approval based on the NeflgArd Phase 3 trial. But among the newer entrants in IgAN, Fabhalta is the first to cross that line.

Vera Therapeutics’ Trutakna (atacicept-vymj) received accelerated approval on July 7, 2026, just ten days before Fabhalta’s traditional approval. Trutakna’s label explicitly states that “continued approval may be contingent upon verification and description of clinical benefit in the ongoing ORIGIN 3 trial,” with eGFR results expected in Q3 2026. Otsuka’s Voyxact (sibeprenlimab) also holds accelerated approval. Vertex’s povetacicept has a BLA under review with a November 30 PDUFA date.

That puts Fabhalta in a different regulatory category from its closest competitors. A nephrologist choosing between an accelerated-approved drug and a traditional-approved drug faces a different risk profile. A payer designing a formulary tier can point to the strength of the regulatory backing. And an investor modeling peak sales can assign a lower regulatory risk discount to Fabhalta than to Trutakna or Voyxact, both of which could theoretically face withdrawal if their confirmatory trials fail to verify clinical benefit.

The mechanism question

The IgAN market is now split across three different mechanisms of action. Fabhalta is an oral complement Factor B inhibitor, targeting the alternative complement pathway. Trutakna is a dual BAFF/APRIL inhibitor, targeting the adaptive immune response that drives autoantibody production. Tarpeyo is a targeted-release corticosteroid that reduces galactose-deficient IgA1 production in the gut. Voyxact is an APRIL inhibitor. And Vertex’s povetacicept, if approved, would be another BAFF/APRIL inhibitor.

Different mechanisms mean different patient populations may respond better to one drug than another. They also mean payers may be willing to cover multiple drugs if the mechanisms are sufficiently differentiated. But they also mean head-to-head comparisons are difficult without direct trial data, which nobody has run yet.

Fabhalta’s safety profile carries one specific constraint: it requires a Risk Evaluation and Mitigation Strategy (REMS) program because complement inhibition increases the risk of serious infections caused by encapsulated bacteria. Patients must receive appropriate vaccinations before starting treatment. That is a real-world friction point for prescribing that Trutakna, which is self-administered via weekly subcutaneous autoinjector, does not share to the same degree.

What to watch

The next inflection point in IgAN is Trutakna’s ORIGIN 3 eGFR readout in Q3 2026. If Vera’s confirmatory data shows a significant slowing of kidney function decline, Trutakna could convert to traditional approval and close the regulatory gap with Fabhalta. If it does not, Fabhalta’s traditional approval becomes an even bigger competitive advantage. Vertex’s November 30 PDUFA for povetacicept adds another entrant to an already crowded field.

Novartis has the scale and nephrology commercial infrastructure that Vera and Calliditas lack. The company’s Q2 2026 earnings call on July 21 reaffirmed 2026 guidance, with oncology offsetting Entresto weakness. Fabhalta is still early in its commercial trajectory, but the traditional approval gives Novartis a cleaner story to tell payers and prescribers than competitors carrying the “accelerated” asterisk.

For more on how Novartis positions its portfolio, see our analysis of Celcuity’s Revtorpyk approval and the Novartis Piqray problem.

Source: Novartis press release | Vera Therapeutics Trutakna approval | FDA Novel Drug Approvals 2026